PHASEBIO PHARMA Shareholders Equity per Share

Shareholders Equity per Share of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shareholders Equity per Share growth rates and interactive chart.


Highlights and Quick Summary

  • Shareholders Equity per Share for the quarter ending June 29, 2021 was -0.4 (a -248.61% decrease compared to previous quarter)
  • Year-over-year quarterly Shareholders Equity per Share decreased by -368.55%
  • Annual Shareholders Equity per Share for 2020 was -0.87 (a -139.76% decrease from previous year)
  • Annual Shareholders Equity per Share for 2019 was 2.18 (a -77.28% decrease from previous year)
  • Annual Shareholders Equity per Share for 2018 was 9.6 (a -3206.67% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shareholders Equity per Share of PHASEBIO PHARMA

Most recent Shareholders Equity per Shareof PHAS including historical data for past 10 years.

Interactive Chart of Shareholders Equity per Share of PHASEBIO PHARMA

PHASEBIO PHARMA Shareholders Equity per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.4 0.27
2020 -0.86 0.15 0.92 1.86 -0.87
2019 2.18 2.47 2.92 1.8 2.18
2018 9.6 12.48 0.0 0.0 9.6
2017 0.0 -0.31
2016 0.09

Business Profile of PHASEBIO PHARMA

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.